Science & Medicine

Breaking Biotech

Matthew Lepoire

Matt breaks down relevant biotech stocks, analyzing their data and determining if they are a good investment.

Episodes

10 episodes

Video Sponsor - http://workinbiotech.com/ In this episode, I go through a company called Vaxxinity, who are trying to develop vaccines for t...

00:45:36May 8, 2022

In this episode, I take a look at 6 different biotechs and talk about recent updates in each one. Here is the breakdown: BTAI - 1:00 TGTX -...

00:43:59Apr 21, 2022

Achieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The drug has been available in Eastern Europe for...

00:28:19Apr 1, 2022

Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout fail...

00:33:19Mar 5, 2022

Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export...

00:33:42Feb 22, 2022

The NASH space has seen some setbacks in the last couple years, but a few players continue to make nice progress on their clinical trials. M...

00:37:28Feb 7, 2022

CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC currently affects around 130K pati...

00:35:09Jan 29, 2022

CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA benefitted the most from this by d...

00:42:53Jan 9, 2022

ALXO announces new HR-MDS data that disappoints! I talk about the comparison to Magrolimab data and why I think ALXO is still a buy. LGVN pu...

00:41:29Jan 3, 2022

Curis is an oncology company trying to develop an inhibitor of IRAK-4. They have shown positive results in AML/MDS in spliceosome/FLT3 mutat...

00:48:17Dec 12, 2021